InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
VTL | Settlement of Dispute (Price Sensitive) | PRICE SENSITIVE | 17/09/24 | |
VTL | Financial Reporting FY24 Update (Price Sensitive) | PRICE SENSITIVE | 16/09/24 | |
VTL | Trading Halt (Price Sensitive) | PRICE SENSITIVE | 16/09/24 | |
VTL | Trading Halt (Price Sensitive) | PRICE SENSITIVE | 16/09/24 | |
VTL | Half Year Report (Price Sensitive) | PRICE SENSITIVE | 08/02/24 | |
VTL | Dec '23 Quarterly Report (Price Sensitive) | PRICE SENSITIVE | 23/01/24 | |
VTL Settlement of Dispute (Price Sensitive) | |||
17/09/24 | PRICE SENSITIVE | 62.72KB | |
VTL Financial Reporting FY24 Update (Price Sensitive) | |||
16/09/24 | PRICE SENSITIVE | 62.04KB | |
VTL Trading Halt (Price Sensitive) | |||
16/09/24 | PRICE SENSITIVE | 110.81KB | |
VTL Trading Halt (Price Sensitive) | |||
16/09/24 | PRICE SENSITIVE | 110.81KB | |
VTL Half Year Report (Price Sensitive) | |||
08/02/24 | PRICE SENSITIVE | 1.02MB | |
VTL Dec '23 Quarterly Report (Price Sensitive) | |||
23/01/24 | PRICE SENSITIVE | 142.86KB | |